TRT 'open questions' videos: what the science says vs. the hype

What did @popethecoach actually say?

He reported his week-22 labs showed testosterone and estrogen both running too high, while SHBG came back in a good range. His clinic is dropping his testosterone dose from 200mg to 180mg per week, discontinuing enclomiphene, and adding an "e-blocker" for 90 days to address elevated estrogen. He was clear this isn't universal: "this is not needed for 90% of men." He also flagged acne and lower energy as his main symptoms from being out of range.

He framed the whole thing as a dose-calibration story, not a crisis. The takeaway he pushed was "more is not always better," referencing the jump from 160mg to 200mg that apparently overshot his target levels. That's a reasonable summary of what happened, even if the clinical nuance around why it happened is missing.

Does the science back this up?

Mostly, yes. The relationship between supraphysiologic testosterone and elevated estradiol is well-established. Testosterone aromatizes into estradiol via the aromatase enzyme, and higher doses predictably push estrogen higher in many men. The symptoms he described, acne and fatigue, are both documented consequences of estradiol excess in men on TRT.

A 2019 review by Ramasamy et al. in Sexual Medicine Reviews confirmed that estradiol management remains one of the more contested areas of TRT practice, with significant provider variation. The "e-blocker" he references is almost certainly an aromatase inhibitor (AI), most commonly anastrozole. Research on AI use in TRT is genuinely mixed. Helo et al. (2015, Journal of Sexual Medicine) found that aggressive estrogen suppression can impair bone density, lipid profiles, and sexual function. So the 90-day, presumably short-term approach he describes is more defensible than long-term AI use.

Enclomiphene is a selective estrogen receptor modulator sometimes used alongside TRT to preserve LH signaling and testicular function. Its combination with exogenous testosterone is an off-label use with limited long-term data, so stopping it isn't inherently wrong.

What did they get wrong (or right)?

He got the core physiology right, even if he didn't explain it. High-dose testosterone raising estrogen is not a mystery, it's predictable biochemistry. Credit where it's due: he disclosed bad labs publicly instead of just posting progress photos. That's genuinely rare in this content category.

What's missing is context on what "way too high" actually means. Estradiol targets in TRT are genuinely debated. Some clinicians target 20-30 pg/mL, others are comfortable above 40. Without knowing his actual numbers, viewers have no way to evaluate whether the AI was warranted or an overcorrection. The phrase "way too high" is not a clinical standard.

His claim that enclomiphene is something "not needed for 90% of men" is plausible but unverifiable as stated. There's no published prevalence figure for enclomiphene co-prescription rates in TRT patients to validate that specific number.

What should you actually know?

If you're on TRT and seeing similar symptoms, the right move is labs, not self-adjustment. Acne and energy fluctuations overlap with a long list of causes beyond estrogen, including thyroid dysfunction, sleep disruption, and poor injection technique causing testosterone spikes.

AIs are real medications with real side effects. Over-suppression of estrogen in men causes its own problems: low libido, joint pain, mood disruption, and long-term bone density loss. A 2017 paper by Finkelstein et al. in the New England Journal of Medicine showed that estrogen plays a significant role in male libido and fat distribution, meaning you don't want it bottomed out. Short-term AI use under supervision is different from chronic use, but the distinction matters and isn't made clearly in this video.

The "this isn't one size fits all" framing is accurate and worth keeping. TRT protocols vary substantially across individuals based on SHBG levels, injection frequency, body composition, and aromatase activity. His SHBG being in a good range while estrogen ran high suggests the issue is likely aromatase activity or dose, not binding dynamics, which is a useful clinical distinction his video skips over.